Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
Status:
Completed
Trial end date:
2016-08-02
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate safety, efficacy and pharmacokinetics of
sorafenib for the treatment of Japanese patients with anaplastic thyroid carcinoma (ATC) or
locally advanced or metastatic medullary thyroid carcinoma (MTC).